[ad_1]
(HealthDay) – Vitamin K-Free Oral Anticoagulants (NOACs) Have a Higher Risk / Benefit Profile Than Vitamin K (VKA) Antagonists for Patients With Chronic Renal Failure (CK), According to a Report Published online July 16 in the Annals of Internal Medicine.
Jeffrey T. Ha, MBBS, of the University of New South Wales in Sydney, and colleagues discussed the advantages and disadvantages of VKA and NOAC in adults with stage 3 to 5 chronic kidney disease. included for 45 trials involving 34,082 participants on anticoagulants. atrial fibrillation (FA, 11 trials), venous thromboembolism (VTE, 11 trials), thromboprophylaxis (six trials), prevention of access thrombosis by dialysis (eight trials), and cardiovascular disease other than FA (nine trials) .
The researchers found that in FA, NOACs reduced the risk of stroke or systemic embolism and hemorrhagic stroke (hazard ratios of 0.79). [95 percent confidence interval, 0.66 to 0.93] and 0.48 [95 percent confidence interval, 0.30 to 0.76], respectively) with respect to VKA. The effects of NOACs on recurrent VTE or VTE-related deaths were uncertain compared to VKA (hazard ratio 0.72, 95% confidence interval 0.44-1.17). NACOs appeared to reduce the risk of major bleeding compared with VKA in all combined trials (risk ratio, 0.75, 95% confidence interval, 0.56 to 1.01).
"NACOs had a higher risk-benefit profile than VKA in patients with early-stage chronic renal failure, with significant reductions in strokes or systemic embolism and stroke. haemorrhagic fever in AF ", write the authors. "However, there is insufficient evidence to recommend the widespread use of VKA or NOACs to improve clinical outcomes in patients with chronic renal failure and end-stage renal failure." dialysis."
Several authors have revealed financial links with the biopharmaceutical industry.
Apixaban is a safe alternative to warfarin during catheter ablation of atrial fibrillation
Summary / Full text (subscription or payment may be required)
Editorial (a subscription or payment may be required)
Copyright © 2019 HealthDay. All rights reserved.
Quote:
Oral anticoagulants other than vitamin K may be the best for chronic early-stage nephropathy (July 16, 2019)
recovered on July 16, 2019
at https://medicalxpress.com/news/2019-07-non-vitamin-oral-anticoagulants-early-stage-ckd.html
This document is subject to copyright. Apart from any fair use for study or private research purposes, no
part may be reproduced without written permission. Content is provided for information only.
[ad_2]
Source link
